Literature DB >> 27197165

Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors.

Theresia R Kress1, Paola Pellanda2, Luca Pellegrinet3, Valerio Bianchi2, Paola Nicoli4, Mirko Doni4, Camilla Recordati5, Salvatore Bianchi2, Luca Rotta4, Thelma Capra4, Micol Ravà1, Alessandro Verrecchia4, Enrico Radaelli6, Trevor D Littlewood3, Gerard I Evan3, Bruno Amati7.   

Abstract

Tumors driven by activation of the transcription factor MYC generally show oncogene addiction. However, the gene expression programs that depend upon sustained MYC activity remain unknown. In this study, we employed a mouse model of liver carcinoma driven by a reversible tet-MYC transgene, combined with chromatin immunoprecipitation and gene expression profiling to identify MYC-dependent regulatory events. As previously reported, MYC-expressing mice exhibited hepatoblastoma- and hepatocellular carcinoma-like tumors, which regressed when MYC expression was suppressed. We further show that cellular transformation, and thus initiation of liver tumorigenesis, were impaired in mice harboring a MYC mutant unable to associate with the corepressor protein MIZ1 (ZBTB17). Notably, switching off the oncogene in advanced carcinomas revealed that MYC was required for the continuous activation and repression of distinct sets of genes, constituting no more than half of all genes deregulated during tumor progression and an even smaller subset of all MYC-bound genes. Altogether, our data provide the first detailed analysis of a MYC-dependent transcriptional program in a fully developed carcinoma and offer a guide to identifying the critical effectors contributing to MYC-driven tumor maintenance. Cancer Res; 76(12); 3463-72. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197165     DOI: 10.1158/0008-5472.CAN-16-0316

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

2.  MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.

Authors:  Brittany Anderton; Roman Camarda; Sanjeev Balakrishnan; Asha Balakrishnan; Rebecca A Kohnz; Lionel Lim; Kimberley J Evason; Olga Momcilovic; Klaus Kruttwig; Qiang Huang; Guowang Xu; Daniel K Nomura; Andrei Goga
Journal:  EMBO Rep       Date:  2017-02-20       Impact factor: 8.807

Review 3.  Chromatin dependencies in cancer and inflammation.

Authors:  Ivan Marazzi; Benjamin D Greenbaum; Diana H P Low; Ernesto Guccione
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-29       Impact factor: 94.444

4.  ZFP281 Recruits MYC to Active Promoters in Regulating Transcriptional Initiation and Elongation.

Authors:  Zhuojuan Luo; Xiaoxu Liu; Hao Xie; Yan Wang; Chengqi Lin
Journal:  Mol Cell Biol       Date:  2019-11-25       Impact factor: 4.272

5.  A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.

Authors:  Pin Liu; Mengmeng Ge; Junjie Hu; Xiaolei Li; Li Che; Kun Sun; Lili Cheng; Yuedong Huang; Maria G Pilo; Antonio Cigliano; Giovanni M Pes; Rosa M Pascale; Stefania Brozzetti; Gianpaolo Vidili; Alberto Porcu; Antonio Cossu; Giuseppe Palmieri; Maria C Sini; Silvia Ribback; Frank Dombrowski; Junyan Tao; Diego F Calvisi; Ligong Chen; Xin Chen
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

6.  An early Myc-dependent transcriptional program orchestrates cell growth during B-cell activation.

Authors:  Alessandra Tesi; Stefano de Pretis; Mattia Furlan; Marco Filipuzzi; Marco J Morelli; Adrian Andronache; Mirko Doni; Alessandro Verrecchia; Mattia Pelizzola; Bruno Amati; Arianna Sabò
Journal:  EMBO Rep       Date:  2019-07-23       Impact factor: 8.807

7.  MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.

Authors:  Delaney K Sullivan; Anja Deutzmann; Josiah Yarbrough; Maya S Krishnan; Arvin M Gouw; David I Bellovin; Stacey J Adam; Daniel F Liefwalker; Renumathy Dhanasekaran; Dean W Felsher
Journal:  Oncogene       Date:  2022-10-07       Impact factor: 8.756

8.  Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

Authors:  Joyce V Lee; Filomena Housley; Christina Yau; Rachel Nakagawa; Juliane Winkler; Johanna M Anttila; Pauliina M Munne; Mariel Savelius; Kathleen E Houlahan; Daniel Van de Mark; Golzar Hemmati; Grace A Hernandez; Yibing Zhang; Susan Samson; Carole Baas; Laura J Esserman; Laura J van 't Veer; Hope S Rugo; Christina Curtis; Juha Klefström; Mehrdad Matloubian; Andrei Goga
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

9.  Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors.

Authors:  Dalin Wang; Jiming Tian; Zeyu Yan; Qing Yuan; Dan Wu; Xiaoli Liu; Shirong Yang; Shanshan Guo; Jianxun Wang; Yongxiu Yang; Jinliang Xing; Jiaze An; Qichao Huang
Journal:  Mol Ther       Date:  2022-01-24       Impact factor: 12.910

10.  Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription.

Authors:  Paola Pellanda; Mattia Dalsass; Marco Filipuzzi; Alessia Loffreda; Alessandro Verrecchia; Virginia Castillo Cano; Hugo Thabussot; Mirko Doni; Marco J Morelli; Laura Soucek; Theresia Kress; Davide Mazza; Marina Mapelli; Marie-Eve Beaulieu; Bruno Amati; Arianna Sabò
Journal:  EMBO J       Date:  2021-04-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.